TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Endurance Training in Severely Disabled Patients With MS - a Feasibility Study
Brief Summary: In the last decade physical exercise has become an accepted and integrated part of rehabilitation in patients with multiple sclerosis (MS). However, no studies have evaluated whether the most severely disabled patients can tolerate and benefit from exercise therapy. The purpose of this study is therefore to evaluate the feasibility of endurance training in severely disabled patients with MS.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Device: Body-weight supported treadmill, Device: Lokomat | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Device: Body-weight supported treadmill, Device: Lokomat | Intervention Type: DEVICE; Name: Body-weight supported treadmill; Assigned to Arm(s): Arm 1 | Intervention Type: DEVICE; Name: Lokomat; Assigned to Arm(s): Arm 1 | Intervention Type: DEVICE; Name: Body-weight supported treadmill; Assigned to Arm(s): Arm 2 | Intervention Type: DEVICE; Name: Lokomat; Assigned to Arm(s): Arm 2
B: Arm Label: Exercise: Vestibular Rehabilitation; Type: EXPERIMENTAL; Interventions: Other: Exercise: Vestibular Rehabilitation | Arm Label: Exercise Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Arm Label: Wait-listed Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise: Vestibular Rehabilitation; Assigned to Arm(s): Exercise: Vestibular Rehabilitation | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise Control
C: Arm Label: Endurance training; Type: EXPERIMENTAL; Interventions: Behavioral: Endurance training, Behavioral: Standard care | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Intervention Type: BEHAVIORAL; Name: Endurance training; Assigned to Arm(s): Endurance training | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Endurance training, Standard care
D: Arm Label: Task-oriented circuit class training; Type: EXPERIMENTAL; Interventions: Behavioral: Task-oriented circuit class training | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: Task-oriented circuit class training; Assigned to Arm(s): Task-oriented circuit class training | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): Usual Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3b, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.
Brief Summary: The purpose of the protocol is to evaluate the efficacy and safety of Dysport® using 2 mL dilution compared with placebo for the treatment of Cervical Dystonia.


Options:
A: Arm Label: Dysport NG; Type: EXPERIMENTAL; Interventions: Biological: Botulinum toxin type A | Arm Label: Dysport; Type: ACTIVE_COMPARATOR; Interventions: Biological: Botulinum toxin type A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Botulinum toxin type A; Assigned to Arm(s): Dysport NG | Intervention Type: BIOLOGICAL; Name: Botulinum toxin type A; Assigned to Arm(s): Dysport | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Dysport; Type: EXPERIMENTAL; Interventions: Biological: Botulinum toxin type A | Intervention Type: BIOLOGICAL; Name: Botulinum toxin type A; Assigned to Arm(s): Dysport
C: Arm Label: Dysport®; Type: ACTIVE_COMPARATOR; Interventions: Biological: Botulinum toxin type A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Botulinum toxin type A; Assigned to Arm(s): Dysport® | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Alternative SoF; Type: EXPERIMENTAL; Interventions: Other: Alternative summary of findings table format | Arm Label: Current SoF; Type: ACTIVE_COMPARATOR; Interventions: Other: Current summary of findings table format | Intervention Type: OTHER; Name: Alternative summary of findings table format; Assigned to Arm(s): Alternative SoF | Intervention Type: OTHER; Name: Current summary of findings table format; Assigned to Arm(s): Current SoF

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Utility and Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome in Neonates
Brief Summary: The chronic use of opiate medications during pregnancy is a major public health challenge. Prolonged exposure to opiates in utero may result in withdrawal symptoms in infants commonly referred to as neonatal abstinence syndrome (NAS). Signs of NAS may include irritability, high-pitched crying, muscle tightness, seizures, diarrhea, vomiting, poor feeding, and unstable body temperature. Many infants may be treated by supportive (non-pharmacological) therapy by minimizing stimulation, cuddling, responding promptly to hunger cues, and other comfort care. However, some infants continue to show severe symptoms of withdrawal despite these interventions. In these cases, infants may be treated with medications (pharmacological therapy). Although it has been several decades since the first descriptions of NAS, there still remains limited information with regards to the most effective treatment. We hypothesize that medical treatment protocols of NAS with methadone can be optimized by better understanding what the body does to the drug (the population-based pharmacokinetics of methadone).


Options:
A: Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Arm Label: Clonidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clonidine | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Clonidine; Assigned to Arm(s): Clonidine
B: Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Arm Label: Methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Buprenorphine
C: Arm Label: Low lactose formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Low lactose or regular formula | Arm Label: Regular formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Low lactose or regular formula | Intervention Type: OTHER; Name: Low lactose or regular formula; Assigned to Arm(s): Low lactose formula, Regular formula
D: Arm Label: Methadone; Type: N/A; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Calorie-restricted, Ketogenic Diet and Transient Fasting vs. Standard Nutrition During Reirradiation for Patients With Recurrent Glioblastoma: the ERGO2 Study
Brief Summary: Increased glucose metabolism is characteristic for solid tumors. Thereby, glucose is important for the generation of ATP, supply of anabolic substrates and defense against reactive oxygen species in tumor cells. In preclinical models, restricting glucose availability using a ketogenic diet, calorie-restriction or transient fasting inhibits tumor growth.

Therefore, the purpose of the study is to evaluate whether a calorie-restricted, ketogenic diet and transient fasting can enhance the efficacy of reirradiation in patients with recurrent glioblastoma.


Options:
A: Arm Label: Fasting Day First; Type: OTHER; Interventions: Behavioral: Fasting First | Arm Label: Fed Day First; Type: OTHER; Interventions: Behavioral: Fed First | Intervention Type: BEHAVIORAL; Name: Fasting First; Assigned to Arm(s): Fasting Day First | Intervention Type: BEHAVIORAL; Name: Fed First; Assigned to Arm(s): Fed Day First
B: Arm Label: ketogenic diet and transient fasting; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calorie-restricted ketogenic diet and transient fasting | Arm Label: standard nutrition; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: standard nutrition | Intervention Type: DIETARY_SUPPLEMENT; Name: calorie-restricted ketogenic diet and transient fasting; Assigned to Arm(s): ketogenic diet and transient fasting | Intervention Type: DIETARY_SUPPLEMENT; Name: standard nutrition; Assigned to Arm(s): standard nutrition
C: Arm Label: Early Time-Restricted Feeding; Type: EXPERIMENTAL; Interventions: Behavioral: Early Time-Restricted Feeding, Behavioral: Structured Weight Loss Program | Arm Label: Control Schedule; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control Schedule, Behavioral: Structured Weight Loss Program | Intervention Type: BEHAVIORAL; Name: Early Time-Restricted Feeding; Assigned to Arm(s): Early Time-Restricted Feeding | Intervention Type: BEHAVIORAL; Name: Control Schedule; Assigned to Arm(s): Control Schedule | Intervention Type: BEHAVIORAL; Name: Structured Weight Loss Program; Assigned to Arm(s): Control Schedule, Early Time-Restricted Feeding
D: Arm Label: Intermittent Calorie Restriction; Type: EXPERIMENTAL; Interventions: Other: Calorie Restriction | Arm Label: Continuous Calorie Restriction; Type: EXPERIMENTAL; Interventions: Other: Calorie Restriction | Arm Label: Healthy Nutrition; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Calorie Restriction; Assigned to Arm(s): Continuous Calorie Restriction, Intermittent Calorie Restriction

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Calorie-restricted, Ketogenic Diet and Transient Fasting vs. Standard Nutrition During Reirradiation for Patients With Recurrent Glioblastoma: the ERGO2 Study
Brief Summary: Increased glucose metabolism is characteristic for solid tumors. Thereby, glucose is important for the generation of ATP, supply of anabolic substrates and defense against reactive oxygen species in tumor cells. In preclinical models, restricting glucose availability using a ketogenic diet, calorie-restriction or transient fasting inhibits tumor growth.

Therefore, the purpose of the study is to evaluate whether a calorie-restricted, ketogenic diet and transient fasting can enhance the efficacy of reirradiation in patients with recurrent glioblastoma.


Options:
A: Arm Label: Delayed exercise control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
B: Arm Label: WBRT+Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine, Radiation: Whole brain radiation therapy | Arm Label: WBRT+Placebo; Type: ACTIVE_COMPARATOR; Interventions: Other: Placebo, Radiation: Whole brain radiation therapy | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): WBRT+Memantine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): WBRT+Placebo | Intervention Type: RADIATION; Name: Whole brain radiation therapy; Assigned to Arm(s): WBRT+Memantine, WBRT+Placebo
C: Arm Label: ketogenic diet and transient fasting; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calorie-restricted ketogenic diet and transient fasting | Arm Label: standard nutrition; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: standard nutrition | Intervention Type: DIETARY_SUPPLEMENT; Name: calorie-restricted ketogenic diet and transient fasting; Assigned to Arm(s): ketogenic diet and transient fasting | Intervention Type: DIETARY_SUPPLEMENT; Name: standard nutrition; Assigned to Arm(s): standard nutrition
D: Arm Label: Whole Brain Radiation Therapy; Type: EXPERIMENTAL; Interventions: Procedure: Whole Brain Radiation Therapy, Behavioral: Questionnaire | Arm Label: Observation; Type: OTHER; Interventions: Other: Observation, Behavioral: Questionnaire | Intervention Type: PROCEDURE; Name: Whole Brain Radiation Therapy; Assigned to Arm(s): Whole Brain Radiation Therapy | Intervention Type: OTHER; Name: Observation; Assigned to Arm(s): Observation | Intervention Type: BEHAVIORAL; Name: Questionnaire; Assigned to Arm(s): Observation, Whole Brain Radiation Therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab and Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Brief Summary: The investigators propose a treatment strategy where patients are treated with induction chemoimmunotherapy consisting of rituximab + bendamustine for 6 cycles, followed by initiation of maintenance rituximab and lenalidomide among patients achieving an objective response (i.e., at least stable disease with some tumor shrinkage) to induction therapy. The goal of maintenance therapy will be to capitalize on the cytoreduction following induction chemotherapy with a maintenance regimen that has also shown promising activity in CLL, in order to allow for improved PFS in this population.


Options:
A: Arm Label: Bendamustine, rituximab, lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: Rituximab, Drug: Lenalidomide | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine, rituximab, lenalidomide | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Bendamustine, rituximab, lenalidomide | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Bendamustine, rituximab, lenalidomide
B: Arm Label: Ofatumumab; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab | Intervention Type: DRUG; Name: Ofatumumab; Assigned to Arm(s): Ofatumumab
C: Arm Label: Ibrutinib + BR; Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib, Drug: Bendamustine hydrochloride, Drug: Rituximab | Arm Label: Placebo + BR; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bendamustine hydrochloride, Drug: Rituximab, Drug: Placebo | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Ibrutinib + BR | Intervention Type: DRUG; Name: Bendamustine hydrochloride; Assigned to Arm(s): Ibrutinib + BR, Placebo + BR | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Ibrutinib + BR, Placebo + BR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + BR
D: Arm Label: Bendamustine + GA101 + Ibrutinib; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: GA101, Drug: Ibrutinib | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine + GA101 + Ibrutinib | Intervention Type: DRUG; Name: GA101; Assigned to Arm(s): Bendamustine + GA101 + Ibrutinib | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Bendamustine + GA101 + Ibrutinib

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients
Brief Summary: The study is designed to compare sevelamer vs. calcium-based phosphate binder in hemodialysis patients to achieve full-scale of medical care, including reduction of atherosclerotic risk factors, reduction of vascular access reconstruction rate, and pharmacoeconomic analysis.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Calcium Carbonate (Phosphate Binder); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: 1500 mg/d elemental calcium as calcium carbonate | Intervention Type: DIETARY_SUPPLEMENT; Name: 1500 mg/d elemental calcium as calcium carbonate; Assigned to Arm(s): Calcium Carbonate (Phosphate Binder) | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Lanthanum carbonate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lanthanum carbonate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Sevelamer HCl; Type: EXPERIMENTAL; Interventions: Drug: Sevelamer HCl | Arm Label: Calcium-based binder; Type: ACTIVE_COMPARATOR; Interventions: Drug: Calcium-based phosphate binder | Intervention Type: DRUG; Name: Sevelamer HCl; Assigned to Arm(s): Sevelamer HCl | Intervention Type: DRUG; Name: Calcium-based phosphate binder; Assigned to Arm(s): Calcium-based binder
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer carbonate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sevelamer carbonate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Steroids on Cerebrospinal Fluid Markers of Inflammation and Neuronal Damage After Surgical Aortic Valve Replacement
Brief Summary: The purpose of this study is to investigate if methylprednisolone is effective in reducing the cerebral inflammatory response after open heart surgery with cardiopulmonary bypass.


Options:
A: Arm Label: RIPCcom group; Type: EXPERIMENTAL; Interventions: Procedure: remote ischemic pre and postconditioning (RIPC) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: remote ischemic pre and postconditioning (RIPC); Assigned to Arm(s): RIPCcom group
B: Arm Label: Interventional group; Type: EXPERIMENTAL; Interventions: Device: hemoadsorber for removal of cytokines | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: hemoadsorber for removal of cytokines; Assigned to Arm(s): Interventional group
C: Arm Label: Methylprednisolone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylprednisolone | Arm Label: Placebo (NaCl); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Methylprednisolone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (NaCl)
D: Arm Label: Xenon; Type: EXPERIMENTAL; Interventions: Drug: Xenon | Arm Label: Sevoflurane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevoflurane | Intervention Type: DRUG; Name: Xenon; Assigned to Arm(s): Xenon | Intervention Type: DRUG; Name: Sevoflurane; Assigned to Arm(s): Sevoflurane

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of an Interactive Web-based Platform and a Disease Specific Information Website in Patients With Heart Failure: a 3-arm Randomised Trial.
Brief Summary: The number of people with heart failure is increasing in the western world. Mainly due to better treatment of myocardial infarctions and ageing of the population. The amount of health care workers is unfortunately not increasing. We want to investigate how two electronic devices (a website and an interactive web-based platform) influence the self-care, quality of life, hospitalizations and mortality by delivering care from a distance. We also want to investigate if a higher quality of care is delivered despite of less frequent visits to a nurse and/or doctor. The study takes place in the Netherlands and is a randomized trial. Patients with heart failure, registered by an outpatient heart failure clinic or general practitioner can take part. They will be randomized to 3 groups: group 1 receives standard care, group 2 receives standard care with the website, group 3 receives an adjusted care pathway, with both the website and the interactive web-based platform connected to a telemonitoring system. In this group all routine consultations with heart failure nurses and general practitioner will be substituted by this device.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Do CHANGE | Arm Label: Care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Do CHANGE; Assigned to Arm(s): Intervention
B: Intervention Type: BEHAVIORAL; Name: 6 months readmission rate to hospital; Assigned to Arm(s): N/A
C: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Educational website.; Type: EXPERIMENTAL; Interventions: Other: Educational website (in addition to usual care). | Arm Label: Website and interactive platform with telemonitoring.; Type: EXPERIMENTAL; Interventions: Other: Website and interactive platform with telemonitoring. | Intervention Type: OTHER; Name: Educational website (in addition to usual care).; Assigned to Arm(s): Educational website. | Intervention Type: OTHER; Name: Website and interactive platform with telemonitoring.; Assigned to Arm(s): Website and interactive platform with telemonitoring.
D: Arm Label: Center-based cardiac rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Center-based cardiac rehabilitation | Arm Label: Home-based training with telemonitoring guidance; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based training with telemonitoring guidance | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Center-based cardiac rehabilitation; Assigned to Arm(s): Center-based cardiac rehabilitation | Intervention Type: BEHAVIORAL; Name: Home-based training with telemonitoring guidance; Assigned to Arm(s): Home-based training with telemonitoring guidance

Answer: C